Source link : https://www.newshealth.biz/health-news/base-treatment-decisions-in-metastatic-breast-cancer-on-presence-of-esr1-mutations/
In this exclusive MedPage Today video, Virginia Kaklamani, MD, DSc, of UT Health Sciences Center in San Antonio and co-director of the San Antonio Breast Cancer Symposium (SABCS), discusses a subgroup analysis of the phase III EMERALD trial, which examined variant allele frequencies (VAF) of ESR1 and PIK3CA mutations in estrogen receptor-positive, HER2-negative metastatic breast […]
Author : News Health
Publish date : 2025-01-02 13:30:00
Copyright for syndicated content belongs to the linked Source.
inHealth